Listen

Description

Dermatofibrosarcoma protuberans (DFSP) is a rare, slow-growing skin cancer primarily driven by the COL1A1-PDGFB gene fusion, though recent research identifies alternative fusions like COL6A3-PDGFD. While the disease is generally associated with a positive prognosis, the fibrosarcomatous variant carries a significantly higher risk of metastasis and recurrence. Mohs micrographic surgery has emerged as the superior treatment over wide local excision due to its ability to provide comprehensive margin control and preserve healthy tissue. For advanced or unresectable cases, the tyrosine kinase inhibitor imatinib serves as an effective systemic therapy by blocking oncogenic signaling. Diagnostic accuracy is increasingly supported by molecular testing and Next-Generation Sequencing, which help tailor treatments to specific genetic profiles. Continuous clinical monitoring remains essential for managing long-term outcomes and detecting potential aggressive transformations early.